Return to search

GTCR-backed Sterigenics acquires Gammarad

Sterigenics International, a portfolio company of GTCR, has bought Gammarad. No financial terms were disclosed. Based in Bologna, Italy, Gammarad is a gamma sterilization provider.

PRESS RELEASE

DEERFIELD, Ill.–(BUSINESS WIRE)–Sterigenics International LLC, a leading global provider of contract sterilization, gamma technologies and medical isotopes, and a portfolio company of GTCR, today announced it has acquired Gammarad, Italy’s leading gamma sterilization provider.

Gammarad, established in 1969 and located in Bologna, Italy, provides gamma irradiation sterilization services for the biomedical, pharmaceutical, food packaging, and cosmetics industries.

“With over 4 million cubic feet of processing capability, this is an important piece to the Sterigenics strategy to continue to expand our global footprint and market position as the leading solutions based provider in contract sterilization,” said Philip Macnabb, President of Sterigenics International LLC. “With this second Gamma irradiation site in Western Europe, Sterigenics can now offer redundancy to our current customers as well as those of Gammarad.

The Gammarad acquisition follows an active year of expansion for Sterigenics. In March, Sterigenics acquired Food Technology Service, Inc., and in August acquired Nordion, Inc., creating the only vertically integrated sterilization company in the world.

“In addition to these strategic acquisitions, Sterigenics has committed more than $32 million in growth capital to expand existing facilities across the Americas and Europe,” said Michael Mulhern, CEO of Sterigenics International. “Our continuing desire is to invest in the future of Sterigenics, building a growth oriented company and building upon our global leadership position.”

Headquartered in Deerfield, Illinois, Sterigenics International LLC operates out of 43 facilities across the Americas, Europe and Asia. It is a global leader in outsourced contract sterilization services, gamma technologies and medical isotopes, and its mission is to improve global public health.

About GTCR
Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare and Information Services & Technology industries. The Chicago-based firm pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $10 billion in over 200 companies. For more information, please visit www.gtcr.com.